BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23715647)

  • 41. MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2.
    Zhang Y; Lin C; Liao G; Liu S; Ding J; Tang F; Wang Z; Liang X; Li B; Wei Y; Huang Q; Li X; Tang B
    Oncotarget; 2015 Oct; 6(32):32586-601. PubMed ID: 26452129
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced expression of mutS homolog 2 and mutL homolog 1 affects overall survival in laryngeal squamous cell carcinoma patients: Investigation into a potential cause.
    Gong HL; Shi Y; Shi Y; Wu CP; Cao PY; Zhou L; Xu C
    Oncol Rep; 2013 Sep; 30(3):1371-9. PubMed ID: 23787767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNA-383 suppresses pancreatic carcinoma development via inhibition of GAB1 expression.
    Su QL; Zhao HJ; Song CF; Zhao S; Tian ZS; Zhou JJ
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10729-10739. PubMed ID: 31858540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MicroRNA-30d inhibits the migration and invasion of human esophageal squamous cell carcinoma cells via the post‑transcriptional regulation of enhancer of zeste homolog 2.
    Xie R; Wu SN; Gao CC; Yang XZ; Wang HG; Zhang JL; Yan W; Ma TH
    Oncol Rep; 2017 Mar; 37(3):1682-1690. PubMed ID: 28184915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long non-coding RNA PXN-AS1 suppresses pancreatic cancer progression by acting as a competing endogenous RNA of miR-3064 to upregulate PIP4K2B expression.
    Yan J; Jia Y; Chen H; Chen W; Zhou X
    J Exp Clin Cancer Res; 2019 Sep; 38(1):390. PubMed ID: 31488171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer.
    Park S; Kim J; Eom K; Oh S; Kim S; Kim G; Ahn S; Park KH; Chung D; Lee H
    BMC Cancer; 2019 May; 19(1):419. PubMed ID: 31060525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
    Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
    Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. hsa_circRNA_001587 upregulates SLC4A4 expression to inhibit migration, invasion, and angiogenesis of pancreatic cancer cells via binding to microRNA-223.
    Zhang X; Tan P; Zhuang Y; Du L
    Am J Physiol Gastrointest Liver Physiol; 2020 Dec; 319(6):G703-G717. PubMed ID: 32878470
    [TBL] [Abstract][Full Text] [Related]  

  • 51. G-protein-coupled receptor kinase 2 in pancreatic cancer: clinicopathologic and prognostic significance.
    Zhou L; Wang MY; Liang ZY; Zhou WX; You L; Pan BJ; Liao Q; Zhao YP
    Hum Pathol; 2016 Oct; 56():171-7. PubMed ID: 27346572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer.
    Li M; Zhao ZW
    Med Oncol; 2012 Jun; 29(2):970-6. PubMed ID: 21660619
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
    Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma.
    Que R; Ding G; Chen J; Cao L
    World J Surg Oncol; 2013 Sep; 11():219. PubMed ID: 24007214
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
    Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
    Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Over-Expression of Alpha-Enolase as a Prognostic Biomarker in Patients with Pancreatic Cancer.
    Sun L; Guo C; Cao J; Burnett J; Yang Z; Ran Y; Sun D
    Int J Med Sci; 2017; 14(7):655-661. PubMed ID: 28824297
    [No Abstract]   [Full Text] [Related]  

  • 57. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression.
    Zhang Y; Chen Z; Li MJ; Guo HY; Jing NC
    Biomed Pharmacother; 2017 Jan; 85():264-271. PubMed ID: 27887846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer.
    Qin Y; Dang X; Li W; Ma Q
    Oncol Res; 2013; 21(6):353-63. PubMed ID: 25198665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of HAX-1 gene expression in esophageal squamous cell carcinoma.
    Li M; Tang Y; Zang W; Xuan X; Wang N; Ma Y; Wang Y; Dong Z; Zhao G
    Diagn Pathol; 2013 Mar; 8():47. PubMed ID: 23531395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. microRNA-195-Cdc42 axis acts as a prognostic factor of esophageal squamous cell carcinoma.
    Sun N; Ye L; Chang T; Li X; Li X
    Int J Clin Exp Pathol; 2014; 7(10):6871-9. PubMed ID: 25400770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.